{"id":"NCT04233216","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)","officialTitle":"A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-03-18","primaryCompletion":"2022-11-21","completion":"2023-11-01","firstPosted":"2020-01-18","resultsPosted":"2023-12-08","lastUpdate":"2024-12-27"},"enrollment":35,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"ISL","otherNames":["Islatravir","MK-8591"]},{"type":"DRUG","name":"DOR","otherNames":["Doravirine","MK-1439"]},{"type":"DRUG","name":"DOR/ISL","otherNames":["Doravirine/Islatravir","MK-8591A"]},{"type":"DRUG","name":"Placebo to ISL","otherNames":[]},{"type":"DRUG","name":"Placebo to DOR","otherNames":[]}],"arms":[{"label":"ISL + ART","type":"EXPERIMENTAL"},{"label":"DOR + ART","type":"EXPERIMENTAL"},{"label":"DOR/ISL + ART","type":"EXPERIMENTAL"},{"label":"Placebo + ART","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination with failing antiretroviral therapy (ART).","primaryOutcome":{"measure":"Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Compared to Placebo Treatment","timeFrame":"Day 1 (baseline) and Day 8","effectByArm":[{"arm":"DOR/ISL + ART","deltaMin":85.7,"sd":null},{"arm":"Placebo + ART","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":98,"countries":["United States","Australia","Canada","Chile","Colombia","France","Germany","Italy","Japan","Peru","Portugal","Puerto Rico","Russia","South Africa","South Korea","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26356&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":7},"commonTop":["Diarrhoea","COVID-19","Creatinine renal clearance decreased","Chest pain","Lymphocyte count decreased"]}}